Piramal Life Sciences to invest in R&DIllustrative image – not actual.

Piramal Life Sciences, an R&D arm of Piramal Group is likely to invest Rs 200 crore to discover and develop new chemical entitities (NCEs) and Novel Drug Delivery Systems (NDDSs) by 2011.

The company has started a programme to discover and develop NCEs and NDDSs in select therapeutic areas, including cancer, inflammation, diabetes/metabolic disorders and infectious diseases with a pipeline of 14 molecules in different phases of development. The company intends to invest Rs 100 crore each in the proposed R&D activities.

Also See:

Piramal acquires Minrad International (24-Dec-08)

 

← All latest storiesBack to top →